Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (127)	11/12/2001 1:01:17 PM
From: tuck	Respond to of 201

Getting near a possible entry point . . . siliconinvestor.com SAN DIEGO, Nov 8, 2001 /PRNewswire via COMTEX/ -- CardioDynamics International Corporation (Nasdaq: CDIC chart, msgs), the innovator and market leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ(R) noninvasive digital cardiac function monitoring systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its second generation BioZ.com II system. Shipments will commence late in the Company's fourth fiscal quarter 2001. The Company announced that it had achieved its goal of $1,000 per unit material cost reduction with the redesign of the BioZ.com II. These savings are in addition to last year's cost reductions to the BioZ.com of over $500. The new BioZ.com II also offers notable design features including proprietary BioZ Crystal Signal Stabilization (CS2(TM)) and BioZ FlexReport(TM) software. The addition of CS2 to the Company's existing proprietary DISQ(TM) (Digital Impedance Signal Quantifier) technology will allow for enhanced signal stability. The FlexReport allows physicians to design reports, based on their medical specialty and disease population -- customized to meet their individual clinical needs. "We are pleased to announce FDA 510(k) clearance of our second generation BioZ.com," stated Michael K. Perry, CardioDynamics' Chief Executive Officer. "Our commitment is to continually improve our ICG solutions. The addition of CS2 and FlexReport to the Company's proprietary DISQ(TM) technology and ZMARC(TM) algorithm has resulted in the most accurate and user-friendly ICG solution ever developed." Perry added, "In addition to the product design improvements, the BioZ.com II's improved margins will enable us to increase market penetration through additional pricing flexibility." The elements of the BioZ.com II were designed for integration into the Company's original BioZ.com, the BioZ dTEL, and future products. This regulatory approval and the advancements included in this new generation of ICG monitoring eliminate the near-term need to pursue BioZ dTEL product clearance. The BioZ.com II will be the Company's initial solution for the dialysis market.<< snip Gunning for a nibble at $4.40. Cheers, Tuck